China’s Duyiwei Biological Acquires Two Hospitals, One More Soon
This article was originally published in PharmAsia News
Executive Summary
Gansu Duyiwei Biological Pharmaceutical Co. Ltd. plans to acquire Pengxi TCM Hospital, according to the company secretary, which follows two other purchases that include Deyang Better Future Hospital Co. Ltd. at RMB 25 million ($4 million) and Ziyang Jianshunwang Check-up Hospital Co. Ltd. for RMB 40 million.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.